↓ Skip to main content

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial

Overview of attention for article published in The Lancet, March 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Citations

dimensions_citation
156 Dimensions

Readers on

mendeley
149 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial
Published in
The Lancet, March 2012
DOI 10.1016/s0140-6736(11)61619-x
Pubmed ID
Authors

Neil E Fleshner, M Scott Lucia, Blair Egerdie, Lorne Aaron, Gregg Eure, Indrani Nandy, Libby Black, Roger S Rittmaster

Abstract

We aimed to investigate the safety and efficacy of dutasteride, a 5α-reductase inhibitor, on prostate cancer progression in men with low-risk disease who chose to be followed up with active surveillance.

Twitter Demographics

The data shown below were collected from the profiles of 33 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 149 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 4 3%
United Kingdom 2 1%
United States 2 1%
Netherlands 1 <1%
Canada 1 <1%
Colombia 1 <1%
Denmark 1 <1%
Slovenia 1 <1%
Unknown 136 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 18%
Student > Ph. D. Student 18 12%
Student > Postgraduate 16 11%
Student > Doctoral Student 14 9%
Other 13 9%
Other 47 32%
Unknown 14 9%
Readers by discipline Count As %
Medicine and Dentistry 82 55%
Agricultural and Biological Sciences 9 6%
Biochemistry, Genetics and Molecular Biology 5 3%
Psychology 4 3%
Nursing and Health Professions 3 2%
Other 21 14%
Unknown 25 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 July 2022.
All research outputs
#594,049
of 21,724,962 outputs
Outputs from The Lancet
#5,522
of 39,426 outputs
Outputs of similar age
#4,145
of 249,447 outputs
Outputs of similar age from The Lancet
#55
of 528 outputs
Altmetric has tracked 21,724,962 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 39,426 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 65.2. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 249,447 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 528 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.